Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,629 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,170 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03079687 | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Oct 25, 2017 | clinicaltrials |
| NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | approved for marketing | — | — | Tesaro, Inc.INDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2017source: clinicaltrials